Pathophysiology and clinical significance of atherogenic lipoprotein phenotype and small dense LDL particles
نویسندگان
چکیده
منابع مشابه
Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects.
A predominance of small, dense low-density lipoprotein (LDL) is a major component of an atherogenic lipoprotein phenotype, and a common, but modifiable, source of increased risk for coronary heart disease in the free-living population. While much of the atherogenicity of small, dense LDL is known to arise from its structural properties, the extent to which an increase in the number of small, de...
متن کاملSmall, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.
OBJECTIVE The relationship of the structural and functional heterogeneity of HDL particles to protection of LDL against oxidative stress is indeterminate. METHODS AND RESULTS HDL subfractions of defined physicochemical properties were isolated by density gradient ultracentrifugation from normolipidemic human serum (n=8), and their capacity to protect LDL from oxidation was evaluated. Under mi...
متن کاملLipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.
BACKGROUND Recent clinical studies showed that lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a predictor for incident atherosclerotic disease. We have previously shown that among the LDL subfractions, Lp-PLA(2) activity is preferentially associated with the atherogenic small, dense (sdLDL) particles in vitro. We investigated whether Lp-PLA(2) could be a marker of sdLDL in human plasm...
متن کاملFluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
BACKGROUND Although HMG-CoA reductase inhibitors (HMGRIs) are effective lipid-lowering agents, it remains controversial whether these agents also lower dense LDL (dLDL), a predominance of which is considered to contribute to the atherogenicity of the metabolic syndrome. METHODS AND RESULTS In a multicenter, double-blind, randomized, placebo-controlled study, we determined the effect of the HM...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Yugoslav Medical Biochemistry
سال: 2003
ISSN: 0354-3447,1452-8193
DOI: 10.2298/jmh0302101d